
At the insistence of regulators, Sprout Pharmaceuticals has recanted statements made in a press release last week that indicated the Food and Drug Administration had eased various restrictions concerning its controversial female libido pill.
The Sept. 4 press release maintained the agency removed a ban on the use of alcohol with the Addyi pill, a point of contention between Sprout and the FDA for the past few years. The release also suggested the FDA eliminated a safety requirement that physicians and pharmacists had to be certified to prescribe and dispense the medicine, respectively.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.